First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

BACKGROUND: CD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD73 human IgG1λ monoclonal antibody, alone or with durvalumab in patients with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bendell, Johanna, LoRusso, Patricia, Overman, Michael, Noonan, Anne M., Kim, Dong-Wan, Strickler, John H., Kim, Sang-We, Clarke, Stephen, George, Thomas J., Grimison, Peter S., Barve, Minal, Amin, Manik, Desai, Jayesh, Wise-Draper, Trisha, Eck, Steven, Jiang, Yu, Khan, Anis A., Wu, Yuling, Martin, Philip, Cooper, Zachary A., Elgeioushi, Nairouz, Mueller, Nancy, Kumar, Rakesh, Patel, Sandip Pravin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264501/
https://www.ncbi.nlm.nih.gov/pubmed/37016126
http://dx.doi.org/10.1007/s00262-023-03430-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264501/
https://www.ncbi.nlm.nih.gov/pubmed/37016126
http://dx.doi.org/10.1007/s00262-023-03430-6

Ejemplares similares